Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

15.05 -0.25 (-1.63%)
Streaming Delayed Price Updated: 12:00 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Janux Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
S&P 500 Cools From Post-Election Record Highs ↗
The Dow Jones Industrial Average is down triple digits this afternoon, as traders unpack this morning's jobs data. 
Via Talk Markets
Topics Stocks Stocks / Equities
News headline image
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst ↗
Janux Therapeutics reports updated clinical data for JANX007, highlighting significant efficacy, safety, and durability in advanced prostate cancer patients. 
Via Benzinga
News headline image
AT&T Updates 2024 Outlook, Joins ZJK Industrial, Janux Therapeutics, Credo Technology Group And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients ↗
All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels. 
Via Investor's Business Daily
News headline image
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Evaluating Janux Therapeutics: Insights From 6 Financial Analysts ↗
 
Via Benzinga
News headline image
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
From Janux Therapeutics
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For Janux Therapeutics ↗
 
Via Benzinga
News headline image
Navigating 5 Analyst Ratings For Janux Therapeutics ↗
 
Via Benzinga
News headline image
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Analyst Expectations For Janux Therapeutics's Future ↗
 
Via Benzinga
News headline image
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
The Latest Analyst Ratings For Janux Therapeutics ↗
 
Via Benzinga
News headline image
Analyst Ratings For Janux Therapeutics ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts ↗
 
Via Benzinga
News headline image
Janux Therapeutics Announces Updates to Board of Directors
From Janux Therapeutics
Via Business Wire
News headline image
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing ↗
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
Via Benzinga
News headline image
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Why Janux Therapeutics Stock Is Crushing It This Week ↗
Janux's silence about a potential acquisition deal could be golden. 
Via The Motley Fool
News headline image
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI ↗
Although fraught with risk, these biotech exposures bring enormous upside potential. 
Via Talk Markets
News headline image
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Take the Money and Run: 3 Overbought Stocks to Sell ASAP ↗
Although speculators were smart enough to jump on these ideas, they’re currently overbought stocks that may require trimming. 
Via InvestorPlace
News headline image
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come? ↗
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank? 
Via InvestorPlace
News headline image
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. 
Via Benzinga
News headline image
Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday? ↗
Janux Therapeutics may be up for sale amid interest from major pharmaceutical firms. With shares quadrupling this year and a successful equity offering, Janux is making waves in the industry. The... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.